Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

Recruiting

• Conditions: Ischemic Stroke; Oral Anticoagulation; Atrial Fibrillation (AF); Outcome Assessment; Clinical Presentations

• Registration Number: NCT06823466
• Lead Sponsor: University of L'Aquila

Brief Summary

The Advancing knowledge in ischemic Stroke PatiEnts on oRal Anticoagulants (ASPERA) study aims to investigate characteristics of ischemic stroke cases occurring in patients on oral anticoagulation for atrial fibrillation (AF) or other cardioembolic arrhythmias and to characterize short and long-term outcomes associated with different secondary prevention strategies to prevent stroke recurrences. The ASPERA study is a multicenter, observational, both retrospective and prospective real-world study involving acute ischemic stroke patients occurring on oral anticoagulation. The study will encompass a retrospective (ASPERA-R) and prospective (ASPERA-P) data collection. Patient will be recruited consecutively at different emergency services and stroke units worldwide. University of L'Aquila (UnivAQ) will be in charge of study coordination, data analysis and management. The duration of ASPERA-R will be of 5-year from the study initiation of the study. Participating centers will be given a 6-month timeframe to enter retrospective data, commencing from the date of study approval.

ASPERA-P duration will be of 2 years of enrollment from the study approval and follow-up of 5 years. (study conclusion after 7 years of approval). Inclusion criteria will be: 1.Confirmed diagnosis of ischemic stroke. 2. Availability of at least one neuroimaging exam positive for ischemic lesion(s) consistent with patient symptoms. 3. Ongoing oral anticoagulation at the time of the index ischemic stroke. 4. Prior diagnosis of atrial fibrillation or other cardioembolic arrhythmias. 5. Written informed consent provided by the patient himself or by proxy. Patients with Symptoms not indicative of acute stroke, ongoing intravenous or subcutaneous anticoagulation at the time of stroke will be excluded. ASPERA-R: characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. The primary outcome will be: ASPERA-R : characterization of demographic, clinical and neuroimaging features of ischemic stroke cases occurring on oral anticoagulants. ASPERA-P: risk of ischemic stroke recurrence of ischemic stroke cases occurring on oral anticoagulants across different secondary preventive strategies (i.e., maintaining the same type of oral anticoagulation versus switching to a different secondary prevention strategy) at 90 days, 1 and 5 years after the index stroke. Additionally, the study will aim to investigate the risk of safety events (hemorrhagic transformation, intracranial hemorrhage, other major bleeding events, any bleeding events, death due to any cause), risk of other major ischemic events (transient ischemic attack, myocardial infarction, death due to vascular causes) at each follow-up and to identify demographic, clinical and neuroimaging features of ischemic stroke recurrences.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-02
• Study First Submitted QC: 2025-02-06
• Study Start: 2025-02-12
• Last Update Submitted: 2025-02-17
• Study First Posted: 2025-03-25
• Last Update Posted: 2025-03-25
• Primary Completion: 2027-02-12
• Study Completion: 2031-02-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Age ≥18 years at the time of the index ischemic stroke.
• Confirmed diagnosis of ischemic stroke according to the World Health Organization (WHO) definition.
• Availability of at least one neuroimaging exam (either a non-contrast computed tomography [NCCT] or magnetic resonance imaging [MRI] of the brain) demonstrating one or more ischemic lesions consistent with patient symptoms.
• Ongoing oral anticoagulation at the time of the index ischemic stroke, defined as the last intake within 48 hours prior to stroke symptom onset for patients on direct oral anticoagulants (DOACs), or an international normalized ratio (INR) of ≥1.5 in patients on vitamin K antagonists (VKAs), regardless of the time elapsed between the last intake and stroke symptom onset.
• Prior diagnosis of AF or other cardioembolic arrhythmias.

Exclusion Criteria

• Symptoms not indicative of acute stroke (i.e., syncope, tonic or clonic activity, dizziness alone, confusion and amnesia alone, chronic or subacute development of focal neurological deficit).
• Ongoing parenteral (intravenous or subcutaneous) anticoagulation at the time of the index event, including bridging with heparin in patients initiating VKA.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ASPERA-R Primary Outcome Measure: Baseline demographic characteristics	At the baseline (index ischemic stroke onset/hospital admission)	Baseline demographic characteristics of ischemic stroke cases occurring on oral anticoagulants: mean age (years), sex (proportion of males and females), ethnicity (proportion of non-Hispanic White, Hispanic White, Black, Asian, other ethnicities), mean weight (Kg), mean height (cm), median BMI
ASPERA-R Primary Outcome Measure: Baseline clinical characteristics	At the baseline (index ischemic stroke onset/hospital admission)	Baseline clinical characteristics: type of oral anticoagulation at the time of index ischemic stroke (proportion of patients on DOAC or VKA), ischemic stroke clinical severity (median National Insititue of Health Stroke Scale - NIHSS), type of clinical presentation (proportion of patients with anterior or posterior circulation stroke), competing stroke etiology (proportion of patients with large-artery-atherosclerosis or lacunar or other determined or undetermined etiology), risk factors (proportion of patients with hypertension, dyslipidemia, diabetes, history of prior stroke/transient ischemic attack, ischemic cardiopaty, peripheral artery disease, chronic kidney or liver failure), acute ischemic stroke treatment (proportion of patients who undergo intravenous thrombolysis or endovascular thrombectomy)
ASPERA-R Primary Outcome Measure: Baseline Neuroimaging characteristics	At the baseline (index ischemic stroke onset/hospital admission)	Baseline Neuroimaging characteristics: large vessel occlusion (proportion of patients with large vessel occlusion), site of large vessel occlusion (proportion of patients with anterior or middle or posterior cerebral arteries occlusion), degree of large vessel occlusion (according to the modified treatment in cerebral infarction - mTICI - score: from 0 - no perfusion - to 3 - complete perfusion), median number of new ischemic lesion(s) at neuroimaging, site of new ischemic lesion(s) at neuroimaging (anterior or posterior circulation, right or left hemisphere or bilateral), presence of hemorrhagic infarction at neuroimaging, degree of hemorrhagic infarction at neuroimaging (according to the Heidelberg classification system: Hemorrhagic Infarction - Small petechiae along the margins of the infarcted area or more confluent petechiae without space-occupying effect (HI2). Parenchymal Hematoma - A hematoma covering less (PH1) or more (PH2) than 30% of the infarcted area.
ASPERA-P Primary Outcome Measure: New ischemic stroke or transient ischemic attack	90-day, 1-year and 5-year post-stroke	New ischemic stroke or transient ischemic attack (proportion of patients with new ischemic stroke or transient ischemic attack)

Secondary Outcome Measures

Name	Time	Method
ASPERA-P Secondary Outcome Measure: Intracranial Hemorrhage	90-day, 1-year and 5-year post-stroke	Intracranial hemorrhage (any type of intracranial hemorrhage)
ASPERA-R Secondary Outcome Measure: All-cause mortality	Discharge and 90-day post-stroke	All-cause mortality (proportion of patients who died due to any cause)
ASPERA-R Secondary Outcome Measure: Vascular death	Discharge and 90-day post-stroke	Vascular death (death due to stroke, myocardial infarction, pulmonary embolism, sudden death or arrhythmias)
ASPERA-R Secondary Outcome Measure: New ischemic stroke or transient ischemic attack	Discharge and 90-day post-stroke	New ischemic stroke or transient ischemic attack (proportion of patients with new ischemic stroke or transient ischemic attack)
ASPERA-R Secondary Outcome Measure: Myocardial infarction	Discharge and 90-day post-stroke	Myocardial infarction (proportion of patients with any type of myocardial infarction)
ASPERA-R Secondary Outcome Measure: Moderate-to-severe bleeding events	Discharge and 90-day post-stroke	Moderate-to-severe bleeding events (proportion of patients with moderate-to-severe bleedings as defined according to the GUSTO bleeding classification): GUSTO severe or life-threatening bleeding is defined as either intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention. GUSTO moderate bleeding is defined as bleeding requiring transfusion, but not resulting in haemodynamic compromise.
ASPERA-R Secondary Outcome Measure: Intracranial hemorrhage	Discharge and 90-day post-stroke	Intracranial hemorrhage (any type of intracranial hemorrhage)
ASPERA-R Secondary Outcome Measure: Ordinal distribution of modified Rankin Scale scores	Discharge and 90-day post-stroke	Ordinal distribution of modified Rankin Scale scores (proportion of patients within each category of the modified Rankin Scale): Symptoms without any disability (score of 1), Symptoms with mild disability (score of 2), Symptoms with mild-to-moderate disability (score of 3), Symptoms with moderate-to-severe disability (score of 4), Symptoms with severe disability (score of 5), Death (score of 6)
ASPERA-P Secondary Outcome Measure: All-cause mortality	90-day, 1-year and 5-year post-stroke	All-cause mortality (proportion of patients who died due to any cause)
ASPERA-P Secondary Outcome Measure: Vascular death	90-day, 1-year and 5-year post-stroke	Vascular death (death due to stroke, myocardial infarction, pulmonary embolism, sudden death or arrhythmias)
ASPERA-P Secondary Outcome Measure: Myocardial infarction	90-day, 1-year and 5-year post-stroke	Myocardial infarction (proportion of patients with any type of myocardial infarction)
ASPERA-P Secondary Outcome Measure: Moderate-to-severe bleeding events	90-day, 1-year and 5-year post-stroke	Moderate-to-severe bleeding events (proportion of patients with moderate-to-severe bleedings as defined according to the GUSTO bleeding classification): GUSTO severe or life-threatening bleeding is defined as either intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention. GUSTO moderate bleeding is defined as bleeding requiring transfusion, but not resulting in haemodynamic compromise.
ASPERA-P Secondary Outcome Measure: Minor bleeding events	90-day, 1-year and 5-year post-stroke	Minor bleeding events (proportion of patients with minor bleedings as defined according to the GUSTO bleeding classification): Any bleedings that is not intracranial haemorrhage or bleeding resulting in haemodynamic compromise necessitating intervention, or bleeding requiring transfusion.
ASPERA-P Secondary Outcome Measure: Any bleeding events	90-day, 1-year and 5-year post-stroke	Any bleeding events (proportion of patients with any bleedings irrespective of their severity)
ASPERA-P Secondary Outcome Measure: Ordinal modified Rankin Scale scores distribution	90-day, 1-year and 5-year post-stroke	Ordinal distribution of modified Rankin Scale scores (proportion of patients within each category of the modified Rankin Scale): Symptoms without any disability (score of 1), Symptoms with mild disability (score of 2), Symptoms with mild-to-moderate disability (score of 3), Symptoms with moderate-to-severe disability (score of 4), Symptoms with severe disability (score of 5), Death (score of 6)

Trial Locations

Locations (47)

Hospital de Santa Maria; 🇵🇹 Lisbon, Portugal

Department of Neurology, Sveti Duh University Hospital; 🇭🇷 Zagreb, Croatia

Copenhagen University Hospital, Bispebjerg Hospital; 🇩🇰 Copenhagen, Denmark

Neurology Department, Assiut University Hospitals; 🇪🇬 Assiut, Egypt

Neurology Department, Faculty of Medicine , Ain Shams University; 🇪🇬 Cairo, Egypt

Neurology Unit, Kobry Elkoba Medical Complex; 🇪🇬 Cairo, Egypt

Université Cote d'Azur UR2CA-URRIS, Unité Neurovasculaire, CHU Hôpital Pasteur 2; 🇫🇷 Nice, France

Department of Neurology, Charite, Berlin Germany and Center for Stroke Research (CSB); 🇩🇪 Berlin, Germany

Department of Neurology, Martin-Luther-University of Halle-Wittenberg; 🇩🇪 Halle (Saale), Germany

Neurological Clinic, Marche Polytechnic University; 🇮🇹 Ancona, Italy

SC Neurologia, Stroke Unit, Ospedale di Venere; 🇮🇹 Bari, Italy

IRCCS Istituto delle Scienze Neurologiche; 🇮🇹 Bologna, Italy

SCA Neurologia, USL Umbria 1; 🇮🇹 Città di Castello, Italy

Azienda Ospedaliero-Universitaria di Ferrara, Arcispedale Sant'Anna; 🇮🇹 Ferrara, Italy

SOD Stroke Unit, Azienda Ospedaliero Universitaria Careggi; 🇮🇹 Florence, Italy

Stroke Unit, Hospital Fabrizio Spazian; 🇮🇹 Frosinone, Italy

University of L'Aquila; 🇮🇹 L'Aquila, Italy

Neurology and Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda; 🇮🇹 Milan, Italy

Neurology and Stroke Unit, AORN Antonio Cardarelli; 🇮🇹 Naples, Italy

UOC Neurologia e Stroke Unit, AOOR. Villa Sofia - Cervello; 🇮🇹 Palermo, Italy

Department of Medicine and Surgery, University of Parma; 🇮🇹 Parma, Italy

Department of Emergency Neurology and Stroke Unit, IRCCS C. Mondino; 🇮🇹 Pavia, Italy

Medicina Interna e d'Urgenza - Stroke Unit, Azienda Ospedaliera di Perugia; 🇮🇹 Perugia, Italy

Department of Emergency Neurology and Stroke Unit, Pescara Hospital; 🇮🇹 Pescara, Italy

Department of Neuroscience, Neurology Unit, S.Maria delle Croci Hospital, AUSL Romagna; 🇮🇹 Ravenna, Italy

Neurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia; 🇮🇹 Reggio Emilia, Italy

UOSD Stroke Unit, Azienda Ospedaliera San Camillo Forlanini; 🇮🇹 Rome, Italy

Fondazione Policlinico Universitario Agostino Gemelli; 🇮🇹 Rome, Italy

UOC Neurologia, Ospedale Provinciale "Madonna del Soccorso"; 🇮🇹 San Benedetto del Tronto, Italy

UOC Stroke Unit, Emergency and Urgency Department, AOU Senese; 🇮🇹 Siena, Italy

ASL Abruzzo 4, G.Mazzini Hospital; 🇮🇹 Teramo, Italy

SOSD Stroke Unit, Department of Head, Neck, and Neuroscience, Udine University Hospital; 🇮🇹 Udine, Italy

Stroke Unit, Neurologia A, Azienda Ospedaliera Universitaria Integrata di Verona; 🇮🇹 Verona, Italy

University Clinic of Neurology, University "Ss.Cyril and Methodius"-Faculty of Medicine; 🇲🇰 Skopje, North Macedonia

Department of Neurology, Jagiellonian University Medical College; 🇵🇱 Krakow, Poland

Lisbon Central University Hospital - ULS São José and Faculdade de Medicina, Universidade de Lisboa; 🇵🇹 Lisbon, Portugal

Elias University Emergency Hospital, Carol Davila University of Medicine and Pharmacy; 🇷🇴 Bucharest, Romania

King Abdulaziz Medical City; 🇸🇦 Riyadh, Saudi Arabia

Vascular Neurology Division National Neuroscience Institute King Fahad Medical City; 🇸🇦 Riyadh, Saudi Arabia

Department of Neurology, Faculty of Medicine, P. J. Safarik University and University Hospital L. Pasteur; 🇸🇰 Kosice, Slovakia

La Paz University Hospital, Universidad Autónoma de Madrid, IdiPAZ Research Institute; 🇪🇸 Madrid, Spain

Department of Medicine, University of Valladolid; 🇪🇸 Valladolid, Spain

University Teaching Hospital St. Gallen; 🇨🇭 St. Gallen, Switzerland

Southmead Hospital, North Bristol NHS Trust; 🇬🇧 Bristol, UK, United Kingdom

St George's University Hospitals NHS Foundation Trust; 🇬🇧 London, UK, United Kingdom

Department of Brain Sciences, Imperial College London; 🇬🇧 London, UK, United Kingdom

Department of Stroke and Neuroscience, Charing Cross Hospital, Imperial College; 🇬🇧 London, UK, United Kingdom